In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
Perry C. Cook, MD, talks about progress made in the use of EZH2 inhibitors for the treatment of patients with FL.
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
Perry C. Cook, MD, discusses the use of tazemetostat for the treatment of patients with relapsed/refractory FL.
Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.
A triplet combo therapy comprising carfilzomib, lenalidomide, and dexamethasone has shown significant efficacy in patients with relapsed or refractory MM.
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
Sangmin Lee, MD, provides an overview of novel strategies for patients with low-risk MDS.
Stay in the know.
OncNet Newsletter